Growth Metrics

Novavax (NVAX) Accounts Payables (2016 - 2025)

Novavax has reported Accounts Payables over the past 16 years, most recently at $24.6 million for Q4 2025.

  • Quarterly results put Accounts Payables at $24.6 million for Q4 2025, down 40.89% from a year ago — trailing twelve months through Dec 2025 was $24.6 million (down 40.89% YoY), and the annual figure for FY2025 was $24.6 million, down 40.89%.
  • Accounts Payables for Q4 2025 was $24.6 million at Novavax, up from $15.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for NVAX hit a ceiling of $386.5 million in Q2 2022 and a floor of $15.2 million in Q3 2025.
  • Median Accounts Payables over the past 5 years was $83.6 million (2023), compared with a mean of $103.3 million.
  • Biggest five-year swings in Accounts Payables: skyrocketed 4411.72% in 2021 and later tumbled 77.43% in 2023.
  • Novavax's Accounts Payables stood at $127.0 million in 2021, then skyrocketed by 70.42% to $216.5 million in 2022, then plummeted by 38.75% to $132.6 million in 2023, then tumbled by 68.65% to $41.6 million in 2024, then tumbled by 40.89% to $24.6 million in 2025.
  • The last three reported values for Accounts Payables were $24.6 million (Q4 2025), $15.2 million (Q3 2025), and $50.6 million (Q2 2025) per Business Quant data.